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The induction of antigen-specific tolerance is critical for
the prevention of autoimmunity and maintenance of im-
mune homeostasis. The immune system’s ability to distin-
guish between self and non-self and between innocuous
and harmful foreign antigens is controlled by mechanisms
of central and peripheral tolerance. Central tolerance is a
well established mechanism that involves deletion of self-
 
reactive T cells upon interaction with bone marrow–
derived dendritic cells (DCs) in the thymus (1, 2). Well
characterized mechanisms of peripheral tolerance include
the induction of cell death or the development of a state of
nonresponsiveness (anergy) of T cells (3, 4). In addition,
active suppression by T regulatory (Tr) cells is also key for
peripheral tolerance (5). However, the mechanisms by
which Tr cells arise in vivo and exert their immunoregula-
tory effects remain to be defined and are the subject of in-
tensive investigation.
 
A role for DCs in the induction of peripheral tolerance
has been supported by several studies (6, 7). At present, the
mechanisms responsible for this process are not clear (8).
However, it is widely assumed that, in the presence of self/
harmless antigens, control of the maturation/activation
state of DCs (7), and/or the subtype of DCs (9, 10) is fun-
damental in the induction of peripheral tolerance. Two pa-
pers, one by Jonuleit et al. in the November 6 issue (11)
and one by Dhodapkar et al. in this issue (12), strongly sug-
gest that immature DCs (iDCs) may control peripheral tol-
erance by inducing the differentiation of human Tr cells.
 
Tr Subsets and Their Role in Peripheral Tolerance.
 
At
present, the term “T regulatory” cell is used to describe a
variety of cells that display regulatory function in vitro or in
vivo and that can be subdivided into a number of subsets
based on expression of cell surface markers, production of
cytokines, and mechanisms of action (13). One of the best
 
characterized subsets of CD4
 
1
 
 Tr cells is defined by its con-
 
stitutive expression of the 
 
a
 
 chain of IL-2R (CD25). Much
evidence indicates that CD4
 
1
 
CD25
 
1
 
 cells arise in the thy-
mus, perhaps via an altered negative selection by self-anti-
gens (5), but that they may need to reencounter the antigen
in the periphery to become fully mature (14). After TCR-
mediated activation, CD4
 
1
 
CD25
 
1 
 
T cells suppress immune
responses in vitro and in vivo via an antigen-nonspecific
mechanism that in some models seems to be independent
of the production of immunosuppressive cytokines (15) and
related to their constitutive expression of CTLA-4 (16, 17).
 
Another subset of CD4
 
1
 
 Tr cells, isolated after cloning
of human T cells activated with alloantigens in the presence
of IL-10, was termed type 1 Tr (Tr1) cells (18). Tr1 cells
specific for recall antigens such as tetanus toxoid can also be
isolated, suggesting that these cells are present in both the
naive and memory pools (unpublished data). Tr1 cells are
distinct from classical Th1 or Th2 cells in that they produce
 
high levels of IL-10, moderate amounts of TGF-
 
b
 
, IFN-
 
g
 
,
and IL-5, low IL-2, and no IL-4 (18). Tr1 cells proliferate
poorly when stimulated via the TCR, and recent evidence
suggests that cytokines such as IL-15 are critical for stimu-
lating their proliferation in vitro (unpublished data). Im-
portantly, Tr1 cells suppress immune responses in vitro and
in vivo via a mechanism that is partially dependent on the
production of the immunoregulatory cytokines IL-10 and
TGF-
 
b
 
 (18, 19).
The CD4
 
1
 
 Tr cells induced by iDCs in vitro (11) or the
CD8
 
1
 
 Tr cells induced in vivo (12) appear to share a key
property with Tr1 cells in that they both produce high lev-
els of IL-10, but no IL-4 or IL-2. However, in contrast to
Tr1 cells, IL-10 appears to be dispensable for the in vitro
suppressive activity of iDC-induced CD4
 
1
 
 Tr cells.
Rather, CD4
 
1
 
 Tr cells primed in vitro by iDCs directly
suppress the proliferative responses of mature Th1 cells via
a mechanism that is antigen independent, requires cell–cell
 
contact, and can be inhibited by addition of exogenous IL-2.
Thus, functionally these Tr cells appear to be more similar
to the CD4
 
1
 
CD25
 
1
 
 Tr cells described above.
 
Overall, the relationship between CD4
 
1
 
CD25
 
1
 
 Tr and
Tr1 cells is currently unclear. It is possible that they are in
fact the same subset of Tr cells in different stages of differ-
entiation. CD4
 
1
 
CD25
 
1
 
 Tr cells may emerge from the
thymus in a partially differentiated state and terminally dif-
 
ferentiate into IL-10– and TGF-
 
b
 
–producing Tr1 cells
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only upon encountering antigen in the periphery. On the
other hand, the observation that murine CD4
 
1
 
CD25
 
1
 
 Tr
cells are comprised by the memory CD45RB
 
low
 
 popula-
tion (17), whereas Tr1 cells can be differentiated from
CD45RA
 
1
 
 naive cells in vitro (18), favors the hypothesis
that CD4
 
1
 
CD25
 
1
 
 Tr cells and Tr1 cells are two distinct Tr
subsets with similar functions.
There is also evidence for the existence of regulatory
cells within the CD8
 
1
 
 T cell subset. Similar to CD4
 
1
 
 Tr
cells, CD8
 
1
 
 Tr cells can be isolated in vitro, after multiple
stimulations, and suppress antigen-specific responses by in-
hibiting IL-2 production and upregulation of CD40L on T
cells and downregulating CD80/86 expression on APCs
(20, 21).
 
DC Maturation as a Control Point for the Induction of Tr
Cells.
 
It is an attractive notion that by controlling the
maturation state of DCs, the activation state of T cells can
be altered. In the absence of inflammation, i.e., under ho-
meostatic conditions, iDCs circulate and take up inhaled or
ingested proteins and dying cells derived from normal cell
turnover (22). Upon phagocytosis in the absence of inflam-
mation, DCs remain immature but may still migrate to re-
gional lymph nodes, a process that could be facilitated by
expression of CCR7 after interaction with apoptotic cells
(Fig. 1; references 22 and 23). In regional nodes, naive T
cells may encounter antigen on iDCs, receive a suboptimal
signal, and, via a process similar to that described in an allo-
geneic system by Jonuleit et al. (11), differentiate into Tr
cells rather than effector T cells (Fig. 1). However, in con-
trast to alloantigens, endocytosed self-antigens cannot be
processed by iDCs to form cell surface–expressed MHC–
peptide complexes (24). Thus, we must hypothesize that
there are stimuli in the lymph node environment that can
allow iDCs to present endocytosed antigens and prime na-
ive T cells to become regulatory cells. Alternatively, iDCs
loaded with apoptotic cells may transfer tissue-derived pep-
tides to a specialized subset of DCs that reside in lymph
nodes and are dedicated to priming CD4
 
1
 
 or CD8
 
1
 
 Tr
cells (reference 25 and Fig. 1).
The primary function of iDCs in vivo would be to
prime Tr cells and generate tolerance to self-antigens, but
iDCs may also induce Tr cells specific for foreign peptides,
as described for CD8
 
1
 
 Tr cells specific for the influenza
matrix peptide (12) or CD4
 
1
 
 Tr cells specific for alloanti-
gens (11). This model is consistent with many data indicat-
ing that the generation of Tr cells depends on the environ-
mental context in which a T cell encounters its antigen (self
or foreign), and that altered expression of costimulatory
Figure 1. Control of periph-
eral tolerance to self-antigens. In
the steady state, iDCs take up
proteins from cells undergoing
normal cell turnover (1a). In the
absence of inflammatory signals,
DCs remain immature but may
still enter regional lymph nodes
(2a). Precursors of Tr cells (Trp)
encounter self-antigen on iDCs
and are primed to become regu-
latory rather than effector T cells
(3a). This step may require that
antigen is “handed off” to spe-
cialized DCs (in blue), which are
dedicated to priming Tr cells.
Primed Tr cells home to the tis-
sue and have suppressive effects,
mediated by inhibitory cytokines
and cell surface molecules, that
ensure that DCs remain in an
immature state in the absence of
inflammation (4a). During an in-
fection, iDCs take up self-anti-
gens in the context of matura-
tion signals (1b). mDCs migrate
to regional lymph nodes (2b) and
prime naive CD41 or CD81 T
cells to become effector T cells
(3b). Here, DC1 cells (in green)
may polarize CD41 cells toward
a Th1 phenotype, whereas DC2
cells (in yellow) would polarize
toward a Th2 phenotype. T ef-
fector cells migrate to the site of
inflammation, where they are
regulated by Tr cells (4b). CD41
or CD81 Tr cells specific for self-antigens regulate immune responses by producing immunoregulatory cytokines such as IL-10 and TGF-b or by directly
suppressing activated Th1 cells via a mechanism that requires cell–cell contact. 
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molecules on APCs and/or exposure to immunoregulatory
cytokines (26) can direct DCs toward tolerogenic rather
than stimulatory cells (27).
In contrast, in the context of an inflammatory environ-
ment when the immune system senses “danger,” DCs en-
counter maturation stimuli (e.g., viral and microbial com-
ponents such as LPS and dsRNA) that cause them to
undergo morphological and functional modifications that
guide mature DCs (mDCs) into regional nodes (28). Here,
mDCs express high levels of co-stimulatory molecules and
stimulatory cytokines that together result in the priming of
antigen-specific immune effectors (28) rather than Tr cells
(Fig. 1). Depending on the ratio of mDCs to naive T cells
(29) or on the presence of different subsets of mDCs (i.e.,
DC1 versus DC2; reference 30), naive T cells may be po-
larized toward distinct effector phenotypes (i.e., Th1 versus
Th2).
 
Is There a Unique DC Subset Dedicated to Priming Tr
Cells?
 
The notion that iDCs prime naive T cells to be-
come Tr is attractive. However, the body of literature sup-
porting a role for specialized subsets of “tolerogenic” DCs
cannot be ignored (31, 32). Indeed, in humans, lymphoid-
derived DCs (the so-called DC2 cells; reference 33) have
been shown to polarize naive T cells toward Th1 cells (34)
and Th2 cells or IL-10–producing T cells when infected by
viruses that induce high levels of IFN-
 
a
 
 production (35).
Interestingly, we have recently shown that IFN-
 
a
 
 syner-
gizes with IL-10 to induce the differentiation of Tr1 cells
(unpublished data), suggesting that via the production of
large amounts of IFN-
 
a
 
, DC2 cells may be critical for the
induction of Tr1 cells in vivo. Thus, upon viral infection,
DC2 cells may simultaneously alert the innate and adaptive
immune responses by producing type I IFNs. In support of
a role for both IL-10 and IFN-
 
a
 
 in regulating responses to
viral infections, it has been shown that in the absence of IL-
10 (36) or signals from IFN-
 
a
 
 (37), the host suffers from
detrimental effects of excessive cellular immune responses
elicited during acute infection.
The primary function of Tr cells that differentiate upon
priming by DC2 cells during viral infections would not be
to maintain tolerance to self, but rather to downregulate T
cell responses to foreign peptides. These Tr cells would be-
come fully mature after repeated antigen stimulation so that
their regulatory effects would only be operational after the
viral infection is cleared. This hypothesis correlates with
many data indicating that multiple stimulations are required
for the induction of functional Tr1 cells (11, 13). To allow
the immune system to control a second infection with the
same agent, we may also speculate that virus-specific Tr
cells are relatively short-lived cells. Indeed, Dhodapkar et
al. (12) report in this issue that the number of matrix pro-
tein–specific Tr cells decreases as quickly as 30 d after in
vivo immunization with iDCs.
 
Mechanisms of Action of Tr Cells.
 
Important issues that
must be addressed are how Tr cells exert their powerful
regulatory effects and on which target cells. After priming,
antigen-specific Tr cells exit the regional nodes and circu-
late in peripheral tissues. We hypothesize that Tr cells can
control/regulate immune responses at the level of both DC
maturation and antigen-specific T cell expansion (Fig. 1).
In the steady state, the major function of Tr cells would
be to maintain DCs in an immature state via cell–cell con-
tact and secretion of cytokines such as IL-10 and TGF-
 
b
 
(Fig. 1). IL-10 downregulates the antigen presenting capac-
ity of many APCs, including bone marrow–derived DCs
and Langerhans cells, by downregulating MHC class II and
a number of costimulatory molecules, including CD80,
CD86, and CD154 (38). Similarly, TGF-
 
b
 
 downregulates
MHC class II and prevents upregulation of CD80 and
CD86 (39, 40).
During an inflammatory response, the major role of Tr
cells resident in the tissue would be to control self-reactive
effector T cells that “accidentally” arise during an immune
response to pathogens. In this situation, cell death occurs
with the consequent uptake of cellular debris and presenta-
tion of both pathogen-derived and self/harmless antigens
by mDCs. Therefore, effector T cells are primed in the
lymph node by mDCs that present both MHC–self-pep-
tide and MHC–foreign peptide complexes. These effector
T cells recirculate, reach the original tissue, and ultimately
mount an effector response against both foreign and self-
antigens. We can hypothesize that Tr cells specific for
many self/harmless antigens already exist at the tissue site
before foreign antigen exposure, and at the onset of inflam-
mation they are rapidly recruited to suppress the effector
function of self-reactive mature T cells. Thus, during an in-
flammatory immune response, the major function of Tr
cells would be to block the effector function of self-reactive
mature T cells. Jonuleit et al. (11) elegantly demonstrate
that IL-10–producing Tr cells can act directly on in vitro–
activated Th1 cells and inhibit antigen-specific proliferative
responses (Fig. 1). Despite the fact that Tr cells differenti-
ated by iDCs produce high levels of IL-10, this cytokine
appeared to be dispensable for their ability to suppress Th1
cell lines activated by mDCs, and Tr cells must make direct
contact with Th1 cells to exert their regulatory effects. This
observation is consistent with previous reports that IL-10
does not have suppressive effects on either mDCs or acti-
vated Th1 cells (26, 38, 41) but does not exclude a role for
IL-10–mediated suppression of iDC and/or activation of
resting T cells, as previously described (18, 26).
Despite the fact that regulation of mature T cell re-
sponses by Tr cells requires cell–cell contact and is not me-
diated by suppressive cytokines, Jonuleit et al. (11) claim
that Tr cell–mediated suppression is not antigen specific.
Therefore, it remains to be determined how Tr cells
present at the tissue site would suppress responses of mature
T cells specific for self-peptides but not the effector func-
tion of T cells specific for foreign pathogenic peptides. One
possibility is that the number of T cells specific for the
harmful antigen is so high that any bystander suppression
mediated by Tr cells is ineffective. Alternatively, it is possi-
ble that some level of specificity in the suppressive effect
mediated by Tr cells does exist. For example, it is possible
that Tr cells deliver a negative signal by recognizing a spe-
cific molecule present only on self-reactive T cells. 
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Finally, we should consider that tissue-resident Tr cells
may have restricted specificity and therefore it is unlikely
that their TCR repertoire will cover all possible self or
harmless antigens. Thus, as discussed above, during an ef-
fector immune response, de novo Tr cells may be primed
by specialized DCs and migrate to the site of infection to
ensure that both the ongoing antipathogen and antiself/
harmless immune responses are self limiting.
Whatever the real mechanism for this ability to distin-
guish between self/harmless and foreign antigens in an in-
flammatory environment may be, evidence that many au-
toimmune diseases are triggered by infectious agents (42)
suggests that it may not be as robust as other responses of
the immune system.
 
Clinical Implications.
 
The observation by Dhodapkar et
al. (12) that immunization with iDCs results in downregu-
lation of CD8
 
1
 
 T cell responses to recall antigens and in-
duction of IL-10–producing T cells, together with the
demonstration by Jonuleit et al. (11) that iDC-induced Tr1
cells can suppress responses of activated T cells, opens new
therapeutic perspectives for the use of iDCs in autoimmune
diseases and allogenic transplantation. Using a protocol
similar to what is described in these two studies, in vitro
pulsing of iDCs with self- (e.g., glutamic acid decarboxy-
lase in diabetes or myelin basic protein in multiple sclerosis)
or alloantigens and subsequent injection could lead to the
in vivo generation of a Tr cell population able to downreg-
ulate self/alloreactivity mediated by both Th1 and CD8
 
1
 
 T
cells. A major caveat to this experimental approach is that
iDCs are not likely to remain in the immature state in vivo
after recirculation and homing to the damaged tissues
where chronic inflammation is always present. Alterna-
tively, vaccination with self/allopeptides together with cy-
tokines able to expand the number of iDCs (e.g., FLT-3
ligand (43) and to preserve their immaturity (e.g., IL-10 or
TGF-
 
b
 
) could be used to induce the Tr cells in vivo. Pre-
clinical studies in animal models of autoimmunity and or-
gan transplantation are warrant to test both approaches.
Another important conclusion that can be drawn from
these two studies is that the use of iDCs for vaccination
with tumor antigens must be avoided. Indeed, this ap-
proach would result in downregulation of immune re-
sponses against the tumor rather than the desired opposite
effect. Therefore, the maturation stage of DCs used for in
vitro loading with tumor antigens should be carefully mon-
itored.
Finally, these studies may provide useful information for
in vitro differentiation and expansion of Tr cells for cellular
therapy of immune-mediated pathologies such as acute or-
gan rejection.
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